Founder mutation for Huntington disease in Caucasus Jews

O. Melamed, D. M. Behar, C. Bram, N. Magal, E. Pras, H. Reznik-Wolf, Z. U. Borochowitz, B. Davidov, R. Mor-Cohen, H. N. Baris*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Huntington disease (HD), an autosomal dominant disorder involving HTT, is characterized by chorea, psychiatric illness and cognitive decline. Diagnosis and age of onset depend on the degree of expansion of the trinucleotide CAG repeat within the gene. The prevalence of HD is known for Europeans but has not been studied in the Israeli population. Between 2006 and 2011 we diagnosed in our adult genetics clinic ten HD probands, nine of whom were Caucasus Jews (CJ) (Azerbaijani), and one Ashkenazi Jewish. We performed haplotype analysis to look for evidence of a founder mutation, and found that of the nine CJ, eight shared the same haplotype that was compatible with the A1 haplogroup. We calculated the coalescence age of the mutation to be between 80 and 150years. Ninety percent of our HD patients are CJ, as are 27% of the HD patients in Israel, although the CJ comprise only 1.4% of the Israeli population. Our findings suggest a higher prevalence of HD among CJ compared to the general Israeli population and are consistent with a recent founder mutation. We recommend a higher degree of suspicion for HD in CJ with subtle clinical findings.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalClinical Genetics
Volume87
Issue number2
DOIs
StatePublished - 1 Feb 2015

Keywords

  • Caucasus Jews
  • Founder mutation
  • Haplotype
  • Huntington disease

Fingerprint

Dive into the research topics of 'Founder mutation for Huntington disease in Caucasus Jews'. Together they form a unique fingerprint.

Cite this